Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

The first company in the United States to begin human clinical trials with its coronavirus vaccine candidate - Moderna MRNA - has announced that it is scheduled to begin the end-of-July clinical trial. The final phase, in collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), would involve 30,000 U.S. participants and use a 100 microgram dose of the vaccine.
The company also said the main goal of the study is to prevent the spread of the coronavirus. The study’s secondary goals include preventing serious illnesses that can lead to hospitalization to treat and prevent infection with SARS-CoV-2, the virus responsible for causing COVID-19. Worn by the news, Moderna's stock rose 0.2% on June 11, when the S&P 500 lost 5.9% on growing concerns about coronavirus infections recurring in the United States.
Investors are increasingly concerned about the increasing number of coronavirus cases in around 20 states. According to data from Johns Hopkins University, the number of US coronavirus infections has exceeded the grim two million mark and more than 113,700 Americans have been killed. The seven-day average of new cases has increased in more than 20 states in the past two weeks, although fewer cases have been registered in some cities and states.
Other vaccine candidates are also seeing progress
Johnson & Johnson JNJ announced that it is accelerating the timeline for initiating a Phase I / II human clinical trial of its vaccine candidate for COVID-19. The phase I / II trial will now start in the second half of July and not in September as previously announced. Strong preclinical data and positive feedback from regulators enabled J&J to accelerate the clinical trial of the recombinant COVID-19 vaccine candidate Ad26.COV2-S. J & J's goal is to provide more than 1 billion doses of the vaccine worldwide if it proves safe and effective.
UK drug maker AstraZeneca AZN also announced the start of the production of the potential University of Oxford coronavirus vaccine ahead of trial results earlier this month and has doubled its capacity to two billion doses. The company also stated not to wait for clinical results expected in August. President Trump also claimed that the country had already procured two million doses of coronavirus disease vaccine that would be "operational" if they "checked for safety" on June 6.
Win Moderna ETFs
The competition for a vaccine opens up short-term opportunities and makes the biotech sector a potential investment area. We are therefore discussing some ETFs that are looking to invest in Moderna:
Loncar Cancer Immunotherapy ETF CNCR
This ETF puts you in touch with a basket of companies that develop therapies to treat cancer using the body's immune system. With 25 shares in the shopping cart, the Moderna company is around 11.8% committed. The fund has an AUM of USD 40.2 million. The product charges 79 basis points of annual fees (see: Biotech ETFs to Benefit from the Latest Advances in Cancer Drugs).
iShares Genomics Immunology and Healthcare ETF IDNA
The fund seeks investment performance in line with the NYSE FactSet Global Genomics and Immuno Biopharma Index before fees and expenses. With Moderna, the company has around 47 securities in its basket, which corresponds to a weight of 11%. It has an AUM of $ 91.7 million and an expense ratio of 0.47% (read: Take advantage of the dynamics of the genomics market with these ETFs).
VanEck Vectors Biotech ETF BBH
The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development, production, marketing, and sale of pharmaceuticals based on genetic analysis and diagnostic equipment. The company has around 24 securities in its shopping basket and is 7.6% invested in Moderna. The AUM is $ 443.5 million and the expense ratio is 0.35% (see: How Do Biotech ETFs Respond to Coronavirus Treatment News?).
Other broader biotech ETFs that companies use to develop tests, vaccines, and therapies for the corona virus include the iShares NASDAQ Biotechnology ETF IBB and the SPDR S & P Biotech ETF XBI.
Would you like to receive important ETF information straight to your inbox?
Zacks' free fund newsletter provides you with the latest news, analysis and best performing ETFs every week. Get it for free >>

Would you like the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click here to get this free report

Johnson Johnson (JNJ): Free stock analysis report

AstraZeneca PLC (AZN): Free stock analysis report

Moderna, Inc. (MRNA): Free stock analysis report

iShares Nasdaq Biotechnology ETF (IBB): ETF research reports

Loncar Cancer Immunotherapy ETF (CNCR): ETF research reports

SPDR SP Biotech ETF (XBI): ETF research reports

VanEck Vectors Biotech ETF (BBH): ETF research reports

iShares Genomics Immunology and Healthcare ETF (IDNA): ETF research reports

To read this article on, click here.

Zacks Investment Research

Would you like the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click here to get this free report

You should check here to buy the best price guaranteed products.

Last News

Tour Disney World's Most Magical, Themed Christmas Trees

Holiday Pies Return to McDonald's for a Limited Time

Chicago P.D. Boss, Jesse Lee Soffer Preview Halstead's Dilemma: 'No Good Options' for Him in Fall Finale

Lauren Boebert posted her own Christmas photo brandishing assault rifles with her kids after a GOP rep was criticized for his

Bill Gates thinks the 'acute phase' of COVID-19 pandemic will be over in 2022, despite the emergence of the Omicron variant

Seven Easy Ways to Save Money in the New Year